Additional file 5: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Figure S2. Proportion of subjects achieving normative HAQ-DI score (≤0.5) at week 12 according to ACR20 responder status in the methotrexate (MTX) add-on study (A) and monotherapy study (B). (EPS 1981 kb

Additional file 3: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Document 2. List of ethical bodies that approved the DARWIN 2 study for each of the 59 study centers. (PDF 68 kb

Additional file 4: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Table S1. Patient-reported outcomes: summary of instruments used and minimally important clinical differences used in this study. Table S2. Baseline patient characteristics. Table S3. Proportion of patients who achieved normative scores at week 12 in the methotrexate add-on and monotherapy studies. (DOCX 34 kb

Additional file 6: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Figure S3. Proportion of subjects achieving normative FACIT-Fatigue score (≥40) at week 12 according to ACR20 responder status in the MTX add-on study (A) and monotherapy study (B). (EPS 1984 kb

Additional file 2: of Effect of filgotinib, a selective JAK 1 inhibitor, with and without methotrexate in patients with rheumatoid arthritis: patient-reported outcomes

Document 1. List of ethical bodies that approved the DARWIN 1 study for each of the 106 study centers. (PDF 129 kb

Additional file 2: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S1. Correlation between synovial markers and serum metabolites. (TIFF 14826 kb

A Comparison of Disease Burden in Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis

<div><p>Objective</p><p>The main objective of this study was to compare disease burden in rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (ax-SpA).</p><p>Methods</p><p>In this cross-sectional study, all the RA (1093), PsA (365) and ax-SpA (333) patients who visited the out-patient clinic of the Hospital of Southern Norway Trust during the year 2013 were included; the RA patients all had a RA diagnosis verified by the treating rheumatologist, the PsA patients all fulfilled the ClASsification for Psoriatic ARthritis (CASPAR) criteria and the ax-SpA patients all fulfilled the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for ax-SpA. Patient-reported health status, demographic variables, medications, and composite scores of disease activity were assessed. The main analyses were performed using General Linear Models adjusted for age, sex and multiple comparisons. Correlation analyses were performed using Spearman’s rho.</p><p>Results</p><p>The reported pain, joint pain, patient’s global assessment and fatigue were similar in PsA and ax-SpA, but significantly lower in RA. The 28-joint Disease Activity Score (DAS28) (0.3±0.1, p = 0.003), Clinical Disease Activity Index (CDAI) (1.0±0.4, p = 0.028) and Routine Assessment of Patient Index Data 3 (RAPID3) (0.4±0.1, p = 0.004) were all significantly higher in PsA vs. RA. RAPID3 showed moderate to high correlation with DAS28 (rho = 0.521, p<0.001) and CDAI (rho = 0.768, p<0.001) in RA and PsA, and with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (rho = 0.902, p<0.001) and Bath Ankylosing Spondylitis Functional Index (BASFI) (0.865, p<0.001) in ax-SpA and PsA.</p><p>Conclusion</p><p>In conclusion, patient- reported outcome measures were similar in our population of PsA and ax-SpA patients, but significantly lower for the RA patients. Composite disease activity measures were lower in RA than in PsA and ax-SpA, but the magnitude of these differences was small and probably not of clinical significance. Our study indicates that disease burden in RA, PsA and ax-SpA may be more similar than previously demonstrated.</p></div

Additional file 7: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S6. Correlation between serum metabolites and synovial IL-1β and IL-8. (TIFF 14826 kb

Additional file 5: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S4. Correlation between serum metabolites and synovial APRIL, CD138, SDF1, IgKappa, and IgMHC. (TIFF 14826 kb

Additional file 6: of Serum metabolomic profiling predicts synovial gene expression in rheumatoid arthritis

Figure S5. Correlation between serum metabolites and synovial MMP1, MMP3, and IL-6. (TIFF 14826 kb